Literature DB >> 10968444

Hyponatraemia associated with lamotrigine in cranial diabetes insipidus.

L Mewasingh, S Aylett, F Kirkham, R Stanhope.   

Abstract

We report the cases of two children with cranial diabetes insipidus who were treated with lamotrigine for seizures and who had accompanying changes in desmopressin requirements. Lamotrigine is a new anticonvulsant chemically unrelated to other existing antiepileptic drugs. Studies suggest it acts at voltage-sensitive sodium channels and also decreases calcium conductance. Both of these mechanisms of action are shared by carbamazepine, which can cause hyponatraemia secondary to inappropriate secretion of antidiuretic hormone. It is possible that the effect of lamotrigine on fluid balance in the cases described is also centrally mediated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10968444     DOI: 10.1016/S0140-6736(00)02613-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  4 in total

Review 1.  Management of hyponatraemia in patients with acute cerebral insults.

Authors:  A Albanese; P Hindmarsh; R Stanhope
Journal:  Arch Dis Child       Date:  2001-09       Impact factor: 3.791

2.  Lamotrigine-induced SIADH in a child with central diabetes insipidus.

Authors:  Huseyin Kılıç; Barış Ekici; Yakup Ergul; Sabiha Keskin; Serap Uysal
Journal:  J Pediatr Neurosci       Date:  2011-01

3.  Patient With Severe Hyponatremia Caused by Adrenal Insufficiency Due to Ectopic Posterior Pituitary Lobe and Miscommunication Between Hypothalamus and Pituitary: A Case Report.

Authors:  Maria Grammatiki; Eleni Rapti; Athanasios C Mousiolis; Maria Yavropoulou; Spyridon Karras; Afroditi Tsona; Michalis Daniilidis; John Yovos; Kalliopi Kotsa
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

4.  The role of lamotrigine in the management of bipolar disorder.

Authors:  Felicity Ng; Karen Hallam; Nellie Lucas; Michael Berk
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.